Showing 4311-4320 of 5771 results for "".
- Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technologyhttps://modernod.com/news/turn-biotechnologies-expands-the-potential-of-its-mrna-platform-by-licensing-unique-artificial-niche-technology/2478826/Turn Biotechnologies announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging. Terms of the deal were not disclosed. The company licensed its AN technology from Stanf
- Johnson & Johnson Vision Receives FDA Approval For Tecnis Eyhance and Tecnis Eyhance Toric II Monofocal IOLshttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-next-generation-monofocal-intraocular-lens-tecnis-eyhance-and-tecnis-eyhance-toric-ii-iols/2478822/Johnson & Johnson Vision announced that the FDA has approved the Tecnis Eyhance and Tecnis Eyhance Toric II IOLs in the United States. The first implantation of Tecnis Eyhance IOL in the US will happen in Texas next week. <
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery Systemhttps://modernod.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/Alcon has announced a nationwide launch of the Clareon IOL with the AutonoMe delivery system in Canada. AutonoMe is an automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the capsular bag in patients undergoing cataract surgery, according to
- Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Wet AMDhttps://modernod.com/news/prevent-blindness-and-bausch-lomb-to-launch-year-long-video-series-to-raise-awareness-of-wet-amd/2478818/Bausch + Lomb and Prevent Blindness, the nation’s oldest volunteer eye health non-profit organization, announced they are joining together for the sixth consecutive year during AMD Awareness Month to raise awareness of age-related macular degeneration (AMD). The two organizations will launch a ye
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- Gemini Therapeutics Initiates GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophyhttps://modernod.com/news/gemini-therapeutics-initiates-gem103-phase-2a-study-as-an-add-on-to-anti-vegf-therapy-for-the-treatment-of-wet-amd-patients-at-risk-for-progressive-vision-loss-due-to-macular-atrophy/2478815/Gemini Therapeutics announced the commencement of a phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD who have, or may be at risk for, macular atrophy (MA) but require ongoing anti-vascular endothelial growth factor (anti-VEGF) treatment. Topline da
- Lensar Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrellhttps://modernod.com/news/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-ofarrell/2478817/Lensar announced the expansion of its board of directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. In addition to serving on the company’s Board of Directors, Ms. Weisner will
- Ocutrx Technologies Appoints Bill Link, PhD, as Chairman of the Ocutrx International Scientific Advisory Boardhttps://modernod.com/news/ocutrx-technologies-appoints-bill-link-phd-as-chairman-of-the-ocutrx-international-scientific-advisory-board/2478813/Ocutrx Technologies has announced the appointment of William “Bill” Link, PhD, as the chairman of the Ocutrx International Scientific Advisory Board. The board plays a key role in guiding and prioritizing Ocutrx’s global research and development investment, while serving as the gu
- Johnson & Johnson Vision Names Peter Menziuso New Worldwide President for Vision Carehttps://modernod.com/news/johnson-johnson-vision-announces-peter-menziuso-as-the-new-worldwide-president-for-vision-care/2478812/Johnson & Johnson Vision announced that Peter Menziuso will assume the role of Worldwide President, Vision Care, for Johnson & Johnson Vision immediately. Mr. Menziuso replaces Swami Raote, who retired at the end of 2020, after a 29-year tenure with Johnson & Johnson. Mr. Menzi